Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant

NIH RePORTER · NIH · N44 · $2,997,218 · view on reporter.nih.gov ↗

Abstract

The contract supports the development of TLR4 agonist within an oil-in-water emulsion as a vaccine adjuvant. The adjuvant development activities are being conducted within the context of vaccines to protect against West Nile virus infection.

Key facts

NIH application ID: 10678482
Project number: 75N93022C00034-0-9999-1
Recipient: HAWAII BIOTECH, INC.
Principal Investigator: DAVID CLEMENTS
Activity code: N44
Funding institute: NIH
Fiscal year: 2022
Award amount: $2,997,218
Award type: —
Project period: 2022-07-05 → 2025-07-05